U.S., June 24 -- ClinicalTrials.gov registry received information related to the study (NCT07662018) titled 'Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors' on June 17.
Brief Summary: To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.
Study Start Date: June 05
Study Type: OBSERVATIONAL
Condition:
Prospective Observational Study
Gemcitabine
Docetaxel
Melphalan
Carboplatin
Stem Cell Transplantation
Pediatric Relapsed
Refractory Germ
Intervention:
DRUG: Gemcitabine (GEM)
Give by Iv
D...